AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: Role for cannabinoid receptors

Neuropharmacology

Volumn 54, Issue 3, 2008, Pages 521-529

  La Rana, G ^a   Russo, R ^a   D'Agostino, G ^a   Sasso, O ^a   Raso, G Mattace ^a   Iacono, A ^a   Meli, R ^a   Piomelli, D ^b   Calignano, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AM404; Mechanical allodynia; Neuropathic pain; Plasma extravasation; Thermal hyperalgesia; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID RECEPTOR; CAPSAICIN; EVANS BLUE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NITRIC OXIDE; PROSTAGLANDIN; SUBSTANCE P; VANILLOID RECEPTOR 1;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; DRUG EFFICACY; EXTRAVASATION; HYPERALGESIA; MALE; NERVE COMPRESSION; NERVE INJURY; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PLASMA; PLASMA EXTRAVASATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE; VENOCONSTRICTION;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EVANS BLUE; HYPERALGESIA; MALE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PAIN MEASUREMENT; PAIN THRESHOLD; PLASMA; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, CANNABINOID; SCIATICA;

EID: 38649118521     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.021     Document Type: Article

References (40)

1. Basile S., Khalil Z., and Helme R.D. Skin vascular reactivity to the neuropeptide substance P in rats with peripheral mononeuropathy. Pain 52 (1993) 217-222
2. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
3. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
4. Bilsland L.G., Dick J.R., Pryce G., Petrosino S., Di Marzo V., Baker D., and Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006) 1003-1005
5. Bisogno T., Maurelli S., Melck D., De Petrocellis L., and Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272 (1997) 3315-3323
6. Bridges D., Ahmad K., and Rice A.S. The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. 133 (2001) 586-594
7. Bridges D., Rice A.S., Egertova M., Elphick M.R., Winter J., and Michael G.J. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119 (2003) 803-812
8. ++ current in NG108-neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106 (1992) 231-232
9. Costa B., Siniscalco D., Trovato A.E., Comelli F., Sotgiu M.L., Colleoni M., Maione S., Rossi F., and Giagnoni G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulate cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. 148 (2006) 1022-1032
10. Cravatt B.F., and Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behaviour. J. Neurobiol. 61 (2004) 149-160
11. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
12. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol 18 2 (2007) 129-140 Review
13. Dray A., Urban L., and Dickenson A. Pharmacology of chronic pain. Trends Pharmacol. Sci. 15 (1994) 190-197
14. Dudhgaonkar S.P., Tandan S.K., Kumar D., Naik A.K., and Raviprakash V. Ameliorative effect of combined administration of inducible nitric oxide synthase inhibitor with cyclooxygenase-2 inhibitors in neuropathic pain in rats. Eur. J. Pain 11 (2007) 528-534
15. Elmes S.J., Jhaveri M.D., Smart D., Kendall D.A., and Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. 20 (2004) 2311-2320
16. Giuffrida A., Beltramo M., and Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther 298 1 (2001) 7-14
17. Henry D.J., and Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186 (1995) 91-94
18. Herzberg U., Eliav E., Bennett G.J., and Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221 (1997) 157-160
19. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., and Malan Jr. T.P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10529-10533
20. Joris J., Costello A., Dubner R., and Hargreaves K.M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain 43 1 (1990) 95-103
21. Kelley B.G., and Thayer S.A. Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur. J. Pharmacol. 496 (2004) 33-39
22. La Rana G., Russo R., Campolongo P., Bortolato M., Manieri R.A., Cuomo V., Iacono A., Mattace Raso G., Meli R., Piomelli D., and Calignano A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404. J. Pharmacol. Exp. Ther 317 (2006) 1365-1371
23. Levy D., Hoke A., and Zochodne D.W. Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain. Neurosci. Lett. 260 (1999) 207-209
24. Lewin G.R., and Mendell L.M. Nerve growth factor and nociception. Trends Neurosci. 16 (1993) 353-359
25. Ma W., and Eisenach J.C. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur. J. Neurosci. 15 (2002) 1037-1047
26. Maccarrone M., Bari M., Lorenzon T., Bisogno T., Di Marzo V., and Finazzi-Agró A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem. 275 (2000) 13484-13492
27. Mitrirattanakul S., Ramakul N., Guerriero A.V., Matsuka Y., Ono T., Iwase H., Mackie K., Faull K.F., and Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 (2006) 102-114
28. Moalem G., and Tracey D.J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51 (2006) 240-264
29. Nackley A.G., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119 (2003) 747-757
30. Nicholson R.A., Liao C., Zheng J., David L.S., Coyne L., Errington A.C., Singh G., and Lees G. Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res. 978 (2003) 194-204
31. Petrosino S., Palazzo E., de Novellis V., Bisogno T., Rossi F., Maione S., and Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52 (2007) 415-422
32. Piomelli D., Beltramo M., and Giuffrida A. Endogenous cannabinoid signaling. Neurobiol. Dis. 5 (1998) 462-473
33. Rakhshan F., Day T.A., Blakely R.D., and Barker E.L. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. 292 (2000) 960-967
34. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 1 (1998) 111-119
35. Wagner R., and Myers R.R. Schwann cells produce tumor necrosis factor alpha: expression in injured and non injured nerves. Neuroscience 73 (1996) 625-629
36. White D.M., and Helme R.D. Release of substance P from peripheral nerve terminals following electrical stimulation of the sciatic nerve. Brain Res. 336 (1985) 27-31
37. Witting A., Weydt P., Hong S., Kliot M., Moller T., and Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89 (2004) 1555-1557
38. Yonehara N., and Yoshimura M. Influence of painful chronic neuropathy on neurogenic inflammation. Pain 92 (2001) 259-265
39. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110
40. Zygmunt P.M., Chuang H., Movahed P., Julius D., and Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396 (2000) 39-42